Torrent Pharmaceuticals Q2 FY27: PAT ₹566 Cr & Rev ₹4,921 Cr

1 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

Metric	Value
Revenue	₹4,921 Cr
Net Profit (PAT)	₹566 Cr

📢 Key Event
Torrent Pharmaceuticals reports record Q1 FY27 revenue of ₹4,921 crores, up 55% YoY, with EBITDA at ₹1,664 crores and net profit of ₹566 crores.

💡 Investor Takeaway
Strong top-line growth and margin stability suggest sustained profitability, but exceptional items may affect near-term earnings clarity.

Torrent Pharmaceuticals reported record Q1 FY27 revenue of ₹4,921 crores, up 55% YoY, driven by organic growth and the JB Pharma acquisition, with operating EBITDA rising 61% to ₹1,664 crores and margins holding at 33.8%. Net profit reached ₹566 crores (11.5% margin), supported by 19% growth in India Rx and 27% growth in Brazil and CDMO segments. The company posted ₹21 crores in exceptional items during the quarter, reflecting integration impacts. Revenue growth in core segments remained robust at 17% YoY, with EBITDA margin stable at 33.3% for base business.

2 Financial Results 🔴 High Importance Neutral 📄 PDF

📢 Key Event
Audio recording of conference call made available

💡 Investor Takeaway
The recording provides access to management commentary on quarterly results for interested investors.

Torrent Pharmaceuticals announced that the audio recording of its conference call discussing financial results for the quarter ended June 30, 2026, is now available on its investor website at the provided URL, as disclosed in a regulatory filing to BSE and NSE under SEBI Listing Obligations and Disclosure Requirements.

📊 Stock Analysis — TORNTPHARM ✨ Ask AI About This

About Torrent Pharmaceuticals Limited (TORNTPHARM)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,49,108.91 Cr P/E: 80.1

View full TORNTPHARM stock details →

📡 Get AI alerts when TORNTPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track TORNTPHARM — Free

💡 Ask AI about this filing

"How will the 55% YoY revenue growth impact full-year profit margins?" "What is the expected contribution of the CDMO segment to future earnings?" "When will the integration of JB Pharma be fully reflected in financials?"

Ask AI Free →

📊 More TORNTPHARM filings

See all TORNTPHARM filings →

🔥 Also filed on 30 July 2026

PARADEEP Paradeep Phosphates Limited Financial Results SYRMA Syrma SGS Technology Limited Offer Document AJANTPHARM Ajanta Pharma Limited Corporate Action GATEWAY Gateway Distriparks Limited Corporate Action AYMSYNTEX AYM Syntex Limited Announcement GILLETTE Gillette India Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when TORNTPHARM files new disclosures

Track TORNTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.